Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03299062 · ClinicalTrials.gov registry record · NA
Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
A NA study, sponsored by University of Arkansas.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT03299062 is a NA study that has completed, run by University of Arkansas. The registered enrollment target is 9 participants.
The verdict
NCT03299062, a NA study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Degenerative dementias including Alzheimer's Disease (AD), Parkinson's Disease with Dementia (PDD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementias (FTLD), Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP) constitute a significant, and growing burden with an estimated cost to the US healthcare system for 2016 of $236 Billion (1). Definitive diagnosis of these dementias is based on pathological criterion upon autopsy, which presents a significant challenge to establish diagnosis in living patients. Although clinical diagnostic criteria have been developed for several of these disorders, including for Alzheimer's Disease (AD) by the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) , Parkinson's Disease (PD) by the United Kingdom Parkinson Disease Brain Bank Diagnostic Criteria (UKPDBB) diagnostic criteria for Parkinson Disease(4) and others, the currently available tests, including the use of imaging markers and Cerebrospinal Fluid (CSF) biological markers do not provide a definite diagnosis since this requires the observation of characteristic neuropathological changes in specific regions of the brain.
Interventions
- DIAGNOSTIC_TEST Cytology and Immunohistochemistry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2021-12-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03299062
The ClinicalTrials.gov registry entry for NCT03299062 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cytology and Immunohistochemistry is the first listed.
NCT03299062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03299062 about?
NCT03299062 is a clinical study titled "Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders". Degenerative dementias including Alzheimer's Disease (AD), Parkinson's Disease with Dementia (PDD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementias (FTLD), Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP) constitute a significant, and growing burden with an estimate...
What is the current status of trial NCT03299062?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2017-11-14. Estimated completion is 2021-12-21.
What interventions are being tested in trial NCT03299062?
The interventions under investigation include: Cytology and Immunohistochemistry (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03299062?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.